tazarotene has been researched along with Chronic Disease in 5 studies
tazarotene: a topical acetylenic retinoid; a topical kerytolytic
tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the therapeutic response to tacalcitol plus PUVA, tazarotene plus PUVA and PUVA monotherapy in patients with chronic plaque-type psoriasis." | 9.10 | A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. ( Hönigsmann, H; Seeber, A; Tanew, A; Tzaneva, S, 2002) |
| " Safety and treatment-emergent adverse events were evaluated throughout." | 6.87 | Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. ( Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018) |
| "To compare the therapeutic response to tacalcitol plus PUVA, tazarotene plus PUVA and PUVA monotherapy in patients with chronic plaque-type psoriasis." | 5.10 | A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis. ( Hönigsmann, H; Seeber, A; Tanew, A; Tzaneva, S, 2002) |
| "Tazarotene in combination with phototherapy is being used clinically for the treatment of plaque psoriasis." | 5.09 | Interactions between tazarotene and ultraviolet light. ( Hecker, D; Kuroda, K; Lebwohl, M; Worsley, J; Yueh, G, 1999) |
| " Safety and treatment-emergent adverse events were evaluated throughout." | 2.87 | Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. ( Gold, LS; Israel, R; Lebwohl, MG; Lin, T; Martin, G; Pariser, DM; Pillai, R; Ramakrishna, T; Sugarman, JL, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gold, LS | 1 |
| Lebwohl, MG | 1 |
| Sugarman, JL | 1 |
| Pariser, DM | 1 |
| Lin, T | 1 |
| Martin, G | 1 |
| Pillai, R | 1 |
| Israel, R | 1 |
| Ramakrishna, T | 1 |
| Tzaneva, S | 1 |
| Hönigsmann, H | 1 |
| Tanew, A | 1 |
| Seeber, A | 1 |
| Waller, JM | 1 |
| Wu, JJ | 1 |
| Murase, JE | 1 |
| Dyson, SW | 1 |
| Kelly, KM | 1 |
| Sander, P | 1 |
| Happe, M | 1 |
| Stücker, M | 1 |
| Hermes, N | 1 |
| Hoffmann, K | 1 |
| Altmeyer, P | 1 |
| Hecker, D | 1 |
| Worsley, J | 1 |
| Yueh, G | 1 |
| Kuroda, K | 1 |
| Lebwohl, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigator-Initiated, Open Label Trial of a Combination of Halobetasol Propionate 0.01% Andtazarotene 0.045% Lotion (Duobrii®) for Plaque Type Psoriasis of the Hands and/or Feet[NCT04720105] | Phase 4 | 22 participants (Actual) | Interventional | 2020-11-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient-reported outcomes evaluated by Dermatology Quality of Life Index (DLQI). DLQi is a 10-item questionnaire, each question is scored from 0 to 3, giving a possible score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 6.24 | 4.94 |
Treatment satisfaction evaluated by a Numerical Rating Scale (NRS). Full scale from 0 to 10, higher score indicates poorer health outcome. (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 1.35 | 1.29 |
Number of participants achieving Palmoplantar Physician Global Assessment (ppPGA) of 0 (clear) or 1 (almost clear/minimal) after 24 weeks of treatment. The ppPGA is based on the Investigators Global Assessment (IGA) modified version 11, specifically applied to the hands and/or feet: 0 (clear), 1 (almost clear/minimal), 2 (mild), 3 (moderate), 4 (marked/moderate-to-severe), 5 (severe) (NCT04720105)
Timeframe: Baseline and Week 24
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Baseline | Week 24 | |
| Participants With Plaque Type Psoriasis | 3.47 | 2.24 |
4 trials available for tazarotene and Chronic Disease
| Article | Year |
|---|---|
Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Topics: Administration, Cutaneous; Chronic Disease; Clobetasol; Dermatologic Agents; Double-Blind Method; Dr | 2018 |
A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque-type psoriasis.
Topics: Adult; Chronic Disease; Combined Modality Therapy; Dermatologic Agents; Dihydroxycholecalciferols; F | 2002 |
[Tazarotene increases the antipsoriatic effect of dithranol in chronic psoriasis].
Topics: Anthralin; Chronic Disease; Dermatologic Agents; Drug Combinations; Drug Synergism; Female; Gels; Hu | 1999 |
Interactions between tazarotene and ultraviolet light.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Gels; Humans; Male; Middle Aged; Nicotinic Acid | 1999 |
1 other study available for tazarotene and Chronic Disease
| Article | Year |
|---|---|
Chronically painful right thumb with pustules and onycholysis. Diagnosis: acrodermatitis continua of Hallopeau.
Topics: Acrodermatitis; Aged; Chronic Disease; Dermatologic Agents; Diagnosis, Differential; Female; Humans; | 2007 |